ResVita Bio announced the appointment of John D. Doux, M.D., M.B.A., to its Board of Directors as the company advances its topical cell therapy platform and prepares to enter the clinic with RVB-003 for Netherton Syndrome.
ResVita is developing a new therapeutic modality that uses genetically engineered, non-pathogenic bacteria to continuously produce therapeutic proteins directly on the skin. The company’s lead candidate, RVB-003, targets Netherton Syndrome, a rare and life-threatening genetic skin disorder that currently has no FDA-approved therapies. The therapy has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.
Dr. Doux is a board-certified dermatologist and Fellow of the American Academy of Dermatology. He currently serves as an analyst at Palo Alto Investors, a physician-led healthcare investment firm, and is a board member of Palvella Therapeutics and Orvida Pharma. He is also a board trustee of the Pachyonychia Congenita Project and co-founded the Dermatology Summit and the Dermatology Innovation Forum.
Prior to his investment and board roles, Dr. Doux maintained a clinical practice in medical and surgical dermatology from 1999 through 2016. He earned his bachelor’s degree and medical degree from Stanford University, completed an internal medicine internship at Brigham and Women’s Hospital, and completed his dermatology residency at Stanford University Medical Center, where he served as Chief Resident. He also received an M.B.A. from The Wharton School of the University of Pennsylvania, where he was recognized as a Palmer Scholar.
ResVita, based in Berkeley, California, is building a pipeline of disease-modifying therapies for serious skin diseases by leveraging its platform’s ability to swap genetic sequences and produce different therapeutic proteins directly at the skin surface.
KEY QUOTES:
“We are thrilled to welcome John to our Board as ResVita prepares to enter the clinic with RVB-003 in Netherton Syndrome and expands our continuous protein therapy platform across a broad range of chronic and rare skin diseases. John is a respected voice in rare skin disease drug development who has spent years championing the case that the orphan disease model can be applied broadly across dermatology, and that thesis is precisely what our platform is built to deliver. His guidance will be invaluable as we build a pipeline of disease-modifying therapies for patients who have long been overlooked.”
Amin Zargar, Ph.D., Chief Executive Officer And Co-Founder, ResVita Bio
“ResVita has built a true platform where genetic sequences can be swapped to direct the continuous, local production of different therapeutic proteins at the skin surface. That modularity, combined with the platform’s preclinical safety and delivery profile, uniquely positions the company to develop disease-modifying therapies for many rare skin diseases with no approved treatments and profound unmet need. I am pleased to join the Board as ResVita advances RVB-003 toward the clinic, and I look forward to partnering with Amin and the team to help bring these therapies to patients.”
John D. Doux, M.D., M.B.A., Board Member, ResVita Bio
